RecruitingNCT06877598

Canada-wide Implementation of a Virtual Sexual Health and Rehabilitation eClinic (SHAReClinic) for Prostate Cancer Patients and Their Partners

Sponsor

University Health Network, Toronto

Enrollment

575 participants

Start Date

Jun 1, 2025

Study Type

OBSERVATIONAL

Conditions

Prostate Cancer Survivorship Sexual Dysfunction Sexual Dysfunction, Physiological Sexual Dysfunction, Psychological Virtual Care Virtual Clinic Implementation of Evidence Based Programs Implementation

Summary

The goal of this observational study is to evaluate the effectiveness of SHAReClinic, a national, virtual Sexual Health and Rehabilitation eClinic designed to support prostate cancer patients and their partners. Specifically, this study aims to assess SHAReClinic's impact on improving sexual function, satisfaction, and relational intimacy after treatment. The primary objective is to evaluate SHAReClinic's effectiveness across participating sites and determine its role in supporting long-term sexual health and well-being. As part of usual care, newly enrolled SHAReClinic patients will receive guided education modules and access to sexual health counselling at key recovery milestones. SHAReClinic seeks to expand access to sexual health care for prostate cancer patients across Canada by providing evidence-based, virtual sexual rehabilitation. Findings from this study will inform best practices in survivorship care and contribute to the development of a national standard for oncology sexual health interventions.

Eligibility

Sex: MALEMin Age: 18 Years

Inclusion Criteria6

Patients who are scheduled for first-line treatment for localized prostate cancer, either through radical prostatectomy (open or robotic) or radiation treatment (brachytherapy, external beam) Alone, or with adjuvant Androgen Deprivation Therapy (ADT) OR
Patients currently undergoing active treatment for prostate cancer OR
Patients who have undergone cancer treatment in the past 6 months
Patients who are hormone and/or chemotherapy-naïve
Patients who have access to a computer or smartphone with internet access
Patients who are 18 years of age or older

Exclusion Criteria5

Patients on ADT alone as primary treatment, and/or patients on chemotherapy
Patients who lack English proficiency
Patients on nitrate therapy or have other contra-indications to phosphodiesterase type 5 inhibitors (PDE5i's)
Patients with medical conditions that would preclude safe sexual activity
Patients who have had previous treatment for PCa